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(>27) had a three-fold increased risk of distant
recurrence compared to patients with a low-risk PS
score. In stage I patients, the estimated risk of distant
recurrence for tumors with high-risk prognostic
scores was signiﬁcantly higher (36%, 95%CI 28%-
46%) than in low-risk PS tumors (15%, 95%CI 8%-
29%, p¼0.0005).
Conclusions: The prediction of risk of distant recur-
rence in resected lung adenocarcinoma patients can be
improved over that obtained by the current standard of
pathological stage by incorporating tumor expression of
proliferation markers (CCP score). Improved risk strati-
ﬁcation can help identify patients in need of additional
treatment and prioritize patients for trials of emerging
new therapies.Strong pharmacological activity of
locally administered next-generation
antisense oligonucleotides (ASOs) in
orthotopic lung cancer mouse modelsMinji Jo, Joanna Schmidt, Tianyuan Zhou,
Xuefeng Wu, Jeffrey R. Crosby, Emily Brand,
Youngsoo Kim, A. Robert MacLeod ISIS
Pharmaceuticals, Inc., Carlsbad, CA
Lung cancer is the second most common cancer type
and the leading cause of cancer-related death in both
men and women in the United States. Although recent
advances in genomic expression proﬁling of lung
cancer has provided more individualized treatment
based on target speciﬁc genetic alteration(s) in pa-
tients, there is a still high unmet medical need as
many important driver mutations remain undruggable
by conventional therapeutic approaches. Antisense
oligonucleotide (ASO) technology offers a novel ther-
apeutic modality to selectively target currently
undruggable pathways. We have recently demon-
strated that systemic delivery of unformulated next
generation (Gen 2.5) ASO targeting human STAT3
mRNA (STAT3-Rx/AZD9150) leads to robust phar-
macological activity in various preclinical animal
models of lung cancer. Importantly, STAT3-Rx/
AZD9150 displayed strong anti-tumor activity in pa-
tients with advanced treatment-refractory lymphoma
as well as non-small cell lung cancer (NSCLC) in
clinical trials*.
Although local delivery of ASOs has been proposed as
a means to treat various pulmonary diseases, ASO
pharmacology in lung tumors has not been previously
evaluated. In this study, we evaluated the activity of anantisense inhibitor (targeting MALAT1 gene) given by
different administration routes {by either a local (intra-
tracheally¼IT) or a systemic (subcutaneously¼SC) de-
livery} in orthotopic lung cancer xenograft models. For
this, human NSCLC A549 or H460 cells were injected to
nude mice via tail vein and 2 weeks later, the tumor-
bearing animals were treated with Gen 2.5 MALAT1 ASO
either IT (at 10 to 20 mg/kg, 3 times per week) or SC (at
25 to 50 mg/kg, 5 times per week) for 3 weeks. Re-
ductions in MALAT1 RNA levels in human tumor cells
and mouse lung were greater with local delivery at lower
doses compared to systemic delivery as assessed by
qRT-PCR or in-situ hybridization using species-speciﬁc
primers/probes (73% reduction at 20 mg/kg by IT
dosing vs 50.5% reduction at 50 mg/kg by SC dosing in
tumors; 72.5% vs 70% reduction in mouse lung at the
same dosing regimen). Moreover, local administration of
ASOs led to no notable increase in liver transaminase
levels compared to systemic administration. Pharmaco-
kinetic property-wise, the local administration showed
greater and more even accumulation of drug in both
tumor and lung tissues compared to the systemic route.
Taken together, these ﬁndings suggest that local
administration of Gen2.5 ASOs to lung malignancies
may be a promising alternative approach to systemic
delivery with greater potency and improved safety pro-
ﬁle, especially in inhibiting lung cancer targets which
cannot be tolerated when depleted systemically.
*Hong D et al. AZD9150, a Next-Generation Antisense Oligo-
nucleotide Inhibitor of STAT3 with Early Evidence of Clinical
Activity in Lymphoma and Lung Cancer. Sci. Transl. Med. 2015
(in press).
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Activating mutations of K-ras, which are found in
approximately 30% of non-small cell lung cancer
(NSCLC), are the most common genetic alterations
associated with tobacco exposure in lung cancer.
Unfortunately, pharmacologic attempts directly tar-
geting K-ras have thus far failed; clearly stating
the need for new strategies to bring clinical beneﬁts
to patients displaying such a molecular proﬁle.
Tumor-promoting inﬂammation is a cancer hallmark,
and it is now apparent that the cytokines and
growth factors released during inﬂammation inﬂuence
